Minu Keshkar, Nisha Rani Agarwal, Kiran Singh, Bharat Bhushan Khurse


Ovarian cancer is the second most common gynaecological cancer. Apoptosis is a normal component of the development and health of
multicellular organisms. Abnormal regulation of apoptosis is probably to contribute to pathogenesis of cancer. Fas, is a transmembrane receptor
that plays a central role in apoptotic signaling. SNPs at -670 of Fas gene alters the function or structure of the encoded proteins, and is sufficient for
its decreased expression and reducing the cell apoptosis leading to malignant transformation.
METHODS: A single-nucleotide polymorphism at -670 of Fas gene promoter (A/G) was examined in a total of 75 blood samples from (25
normal healthy and 50 ovarian cancer), using PCR-RFLP technique.
RESULTS: There was no significant difference found in the genotype prevalence between control and ovarian tumor patients. The Fas -670 GG
genotype was not associated with an increased risk for the development of ovarian tumor (OR=1.0108 95% CI=0.274-3.7201) compared with the
AA genotype.


Apoptosis, Fas, Single-nucleotide Polymorphism.

Full Text:



Nagata S, Golstein P. The Fas death factor. Science 1995;267:


Wajant H (2002). "The Fas signaling pathway: more than a paradigm". Science 296 (5573): 1635–6.

Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169–78.

Thompson CB, Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462.

Huang QR, et al Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol. Immunol. 1997;34:577-582.

Maureen A. Riopel, Amy Spellerberg, Constance A. Griffin, and Elizabeth J. Perlman2 Department of Pathology, The Johns Hopkins Hospital, Baltimore, Mary/and 21287. Genetic Analysis of Ovarian Germ Cell Tumors by Comparative Genomic Hybridization (CANCER RESEARCH 58, 3105-3110. July 15. 1998)

Kanemitsu S, Ihara K, Saifddin A et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 2002;29:1183–8.

Huang QR, Danis V, Lassere M, Edmonds J, Manolios N. Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology (Oxford) 1999;38:645–51.

Lee YH, Kim YR, Ji JD, Sohn J, Song GG. Fas promoter 2670 polymorphism is associated with development of anti-RNP antibodies in systemic lupus erythematosus. J Rheumatol 2001;28: 2008–11.

Lai HC, Sytwu HK, Sun CA et al. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 2003;103:221–5.

Tamandani, DMk; Sobti, RC; Shekari, M CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY Volume: 35 Issue: 3 Pages: 183-186.

H Das, T Koizumi, T Sugimoto, S Chakraborty, T Ichimura, K Hasegawa and R Nishimura: Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR; British Journal of Cancer (2000) 82(10), 1682–1688.

M. Ueda, Y. Terai, K. Kanda, M. Kanemura, M. Takehara, H. Yamaguchi,K. Nishiyama, M. YASUDA & M. Ueki Fas gene promoter -670 polymorphism in gynecological cancer. Int J Gynecol Cancer 2006, 16 (Suppl. 1), 179–182


  • There are currently no refbacks.